Close
Help
signup_email_alerts
Need Help?



Zolmitriptan and the Triptan Era

Submit a Paper


Libertas Analytics


2272 Article Views

Publication Date: 22 Jul 2009

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine: Therapeutics 2009:1 781-785

CMIt journal

517,283 Article Views

6,291,405 Libertas Article Views

More Statistics

Abstract

Zolmitriptan is one of seven triptans available to treat acute migraine attacks. The introduction of these selective serotonin receptor agonists almost 20 years ago has revolutionized acute migraine treatment. Triptans are now first line migraine drugs, and provide acute treatment that is well-tolerated, safe and effective. This commentary reviews the use of zolmitriptan and other triptans, discusses how to maximize their effect, and examines the controversies surrounding this class of medication such as medication-overuse headache, use in migraine aura or prodrome, pediatric use, and important drug interactions.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Our Authors Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES
Our Testimonials
My recent paper in Clinical Medicine Insights: Therapeutics was the third I have published in a Libertas Academica journal.  Again, I was very pleased by the remarkable speed of publication. It took less than seven weeks from submission of the first manuscript version and two weeks from submission of the revision to the appearance of the final article.  When I had unforeseen problems with the transmission of proof corrections because of some software incompatibilities the production team acted immediately and was very helpful.  Over 300 views in less than 3 weeks after publication indicate excellent visibility of the article and of the journal too. Congratulations!
Dr Ruediger Hardeland (University of Goettingen, Germany) What our authors say